- Home
- CTOS vs EYPT Comparison
CTOS vs EYPT Comparison
Compare CTOS & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTOS | EYPT |
|---|---|---|
| Founded | 1988 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | CTOS | EYPT |
|---|---|---|
| Price | $6.31 | $15.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $7.33 | ★ $28.75 |
| AVG Volume (30 Days) | 887.2K | ★ 1.1M |
| Earning Date | 03-03-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,936,513,000.00 | $42,339,000.00 |
| Revenue This Year | $13.19 | N/A |
| Revenue Next Year | $4.90 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 7.39 | N/A |
| 52 Week Low | $3.18 | $3.91 |
| 52 Week High | $6.78 | $19.11 |
Technical Indicators
Market Signals| Indicator | CTOS | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 57.48 | 44.04 |
| Support Level | $5.82 | $15.14 |
| Resistance Level | $6.25 | $18.20 |
| Average True Range (ATR) | 0.20 | 0.86 |
| MACD | 0.04 | -0.37 |
| Stochastic Oscillator | 83.70 | 22.45 |
Price Performance
Historical ComparisonAbout CTOS Custom Truck One Source Inc.
Custom Truck One Source Inc is a one-stop-shop provider of specialty equipment in the electric utility transmission and distribution, forestry, telecom, waste management, rail, and infrastructure end-markets in North America. The company's segment includes Equipment Rental Solutions (ERS), Truck and Equipment Sales (TES), and Aftermarket Parts and Services (APS). It generates maximum revenue from the TES segment. Geographically, it derives a majority revenue from the United States.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.